157 related articles for article (PubMed ID: 17028100)
21. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53.
Keshelava N; Tsao-Wei D; Reynolds CP
Clin Cancer Res; 2003 Aug; 9(9):3492-502. PubMed ID: 12960142
[TBL] [Abstract][Full Text] [Related]
22. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
23. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation.
Chhipa RR; Kumari R; Upadhyay AK; Bhat MK
Exp Cell Res; 2007 Nov; 313(19):3945-58. PubMed ID: 17935714
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.
Buganim Y; Kalo E; Brosh R; Besserglick H; Nachmany I; Rais Y; Stambolsky P; Tang X; Milyavsky M; Shats I; Kalis M; Goldfinger N; Rotter V
Cancer Res; 2006 Nov; 66(22):10750-9. PubMed ID: 17108111
[TBL] [Abstract][Full Text] [Related]
26. DNA binding and selective gene induction by different forms of the p53 protein.
Mayelzadeh F; Martinez JD
Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840
[TBL] [Abstract][Full Text] [Related]
27. Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function.
Ottaggio L; Campomenosi P; Fronza G; Menichini P; Miele M; Moro F; Viaggi S; Zunino A; Abbondandolo A
J Cell Biochem; 2006 Aug; 98(6):1689-700. PubMed ID: 16598767
[TBL] [Abstract][Full Text] [Related]
28. Microtubule-associated protein 1B light chain (MAP1B-LC1) negatively regulates the activity of tumor suppressor p53 in neuroblastoma cells.
Lee SY; Kim JW; Jeong MH; An JH; Jang SM; Song KH; Choi KH
FEBS Lett; 2008 Aug; 582(19):2826-32. PubMed ID: 18656471
[TBL] [Abstract][Full Text] [Related]
29. Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells.
Hill R; Leidal AM; Madureira PA; Gillis LD; Cochrane HK; Waisman DM; Chiu A; Lee PW
DNA Repair (Amst); 2008 Feb; 7(2):239-52. PubMed ID: 18024214
[TBL] [Abstract][Full Text] [Related]
30. Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells.
Zupanska A; Adach A; Dziembowska M; Kaminska B
Cell Signal; 2007 Jun; 19(6):1268-78. PubMed ID: 17321721
[TBL] [Abstract][Full Text] [Related]
31. Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis.
Ohki R; Kawase T; Ohta T; Ichikawa H; Taya Y
Cancer Sci; 2007 Feb; 98(2):189-200. PubMed ID: 17233836
[TBL] [Abstract][Full Text] [Related]
32. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.
Moh MC; Zhang T; Lee LH; Shen S
Carcinogenesis; 2008 Dec; 29(12):2298-305. PubMed ID: 18845560
[TBL] [Abstract][Full Text] [Related]
33. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
34. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.
Okawa ER; Gotoh T; Manne J; Igarashi J; Fujita T; Silverman KA; Xhao H; Mosse YP; White PS; Brodeur GM
Oncogene; 2008 Jan; 27(6):803-10. PubMed ID: 17667943
[TBL] [Abstract][Full Text] [Related]
35. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells.
Liu PY; Chan JY; Lin HC; Wang SL; Liu ST; Ho CL; Chang LC; Huang SM
Mol Cancer Res; 2008 Jul; 6(7):1204-14. PubMed ID: 18644983
[TBL] [Abstract][Full Text] [Related]
36. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression.
Choi BH; Kim CG; Bae YS; Lim Y; Lee YH; Shin SY
Cancer Res; 2008 Mar; 68(5):1369-77. PubMed ID: 18316600
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
Welch C; Chen Y; Stallings RL
Oncogene; 2007 Jul; 26(34):5017-22. PubMed ID: 17297439
[TBL] [Abstract][Full Text] [Related]
38. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.
Fen CX; Coomber DW; Lane DP; Ghadessy FJ
J Mol Biol; 2007 Aug; 371(5):1238-48. PubMed ID: 17610896
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors.
Abel F; Sjöberg RM; Krona C; Nilsson S; Martinsson T
Int J Oncol; 2004 Nov; 25(5):1297-302. PubMed ID: 15492818
[TBL] [Abstract][Full Text] [Related]
40. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.
Becker K; Marchenko ND; Maurice M; Moll UM
Cell Death Differ; 2007 Jul; 14(7):1350-60. PubMed ID: 17380154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
